Key Takeaways
- Pharmacogenomics (PGx) testing is being rolled out across 14 major Canadian hospital networks, up from 3 networks in 2023.
- BC Children’s Hospital’s PGx implementation reduced serious adverse drug events by 31% in the first year of operation.
- Psychiatry, oncology, and cardiology account for 72% of clinically actionable PGx variants identified in Canadian patient populations.
- Canadian companies NovaBay Genomics and PGx Health are competing for hospital panel supply contracts in a market estimated at $180 million by 2028.
Every year, adverse drug reactions send approximately 200,000 Canadians to emergency departments and contribute to an estimated 18,000 deaths a toll that pharmacogenomics researchers have long argued is substantially preventable. The premise is straightforward: genetic variants in the enzymes that metabolize drugs, and in the receptors that drugs target, determine whether a given patient will respond well to a medication, fail to respond at all, or experience a serious adverse reaction. Knowing a patient’s relevant genetic profile before prescribing should lead to better drug choices and better outcomes. That premise is finally being validated at scale in Canadian hospitals.
What Pharmacogenomics Testing Involves
A clinical PGx panel is a laboratory test that sequences or genotypes a set of genes known to influence drug metabolism and drug response. The most commonly tested genes include CYP2D6, CYP2C19, CYP2C9, CYP3A4, SLCO1B1, DPYD, TPMT, and UGT1A1 each of which affects how patients process a specific set of commonly prescribed drugs. A single PGx panel can inform prescribing decisions for dozens of medications, from antidepressants and antipsychotics to statins, anticoagulants, and chemotherapy agents.
The test is typically ordered once results are lifetime-relevant because germline genetic variants don’t change and stored in the patient’s electronic health record for future reference whenever a relevant medication is prescribed. This one-time testing model means the cost, once borne, provides perpetual clinical utility rather than requiring repeat testing.
| Drug Category | Key Genes Tested | Clinical Impact | Proportion of Canadians with Actionable Variant |
|---|---|---|---|
| Antidepressants / Antipsychotics | CYP2D6, CYP2C19 | Dose adjustment, drug switching | ~40% |
| Antiplatelet agents (clopidogrel) | CYP2C19 | Switch to alternative (ticagrelor/prasugrel) | ~30% |
| Statins | SLCO1B1 | Myopathy risk reduction | ~15% |
| Oncology (5-FU, capecitabine) | DPYD | Dose reduction to prevent toxicity | ~8% |
| Oncology (6-MP, azathioprine) | TPMT, NUDT15 | Dose reduction, toxicity prevention | ~10% |
| Anticoagulants (warfarin) | CYP2C9, VKORC1 | Dose optimization | ~35% |
The Hospital Adoption Curve
Fourteen major Canadian hospital networks now have active PGx programs up from just three in 2023 and none at meaningful scale before 2021. The adoption curve has been driven by a combination of factors: the availability of cheaper, faster genotyping panels; the establishment of clinical utility guidelines by the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS); and growing awareness among hospital administrators that the return on investment from PGx programs can be demonstrated within the first year of implementation.
The national rollout plan, coordinated through the Canadian Institutes of Health Research, targets 35 hospital networks by 2028 covering approximately 60% of Canadian tertiary care volume. Implementation is most advanced in British Columbia, Ontario, and Quebec, where provincial health ministries have provided implementation grants to support infrastructure costs.
Commercial Landscape: Canadian Companies
NovaBay Genomics, a Toronto-based molecular diagnostics company, supplies PGx panels to eight of the 14 currently active hospital networks. The company’s NovaPGx panel covers 47 genes and 312 variants and integrates with major hospital laboratory information systems. PGx Health, headquartered in Vancouver, has focused on the outpatient and direct-to-physician market, offering a mail-in saliva collection kit that delivers results through an integrated prescribing decision support platform.
The Bottom Line
Pharmacogenomics is crossing the threshold from niche academic interest to mainstream hospital practice in Canada, driven by compelling cost-benefit evidence, maturing clinical guidelines, and a competitive domestic supplier market. For investors, the $180 million Canadian PGx market by 2028 is attainable for well-positioned companies, but the real prize is integration into electronic prescribing workflows whoever owns that touchpoint will capture recurring clinical utility value every time a relevant drug is prescribed. The companies that successfully embed PGx results into clinical decision support platforms will be the durable winners in this space.